Full Press Release Details
to Participate in Oppenheimer Life Sciences Summit, NY & in Piper
Jaffray 28th Annual Health Care Conference, NY
NEW YORK--(BUSINESS WIRE)--November 21, 2016--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced that the Company
will participate in the upcoming Oppenheimer Life Sciences Summit being
held on November 29, 2016 at the Sofitel Hotel in New York City.
Cellectis will be presenting at the Piper Jaffray 28th Annual Health
Care Conference. Cellectis presentation will take place on November 30,
2016 at 8:00AM US Eastern Time in Lotte New York Palace - 455 Madison
Ave, Track Three - Holmes 1 - 4th Floor.
A live webcast will be available at http://edge.media-server.com/m/p/xbcsg2nz
The replay is available via the same link.
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company's
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering - based on its flagship TALEN
products and meganucleases and pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets. Cellectis is listed on
the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.
Talking about gene editing? We do it. TALEN is a
registered trademark owned by the Cellectis Group.
This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. The
risks and uncertainties include, but are not limited to, the risk that
the preliminary results from our product candidates will not continue or
be repeated, the risk of not obtaining regulatory approval to commence
clinical trials on the UCART product candidates, the risk that any one
or more of our product candidates will not be successfully developed and
commercialized. Further information on the risks factors that may affect
company business and financial performance, is included in filings
Cellectis makes with the Security Exchange Commission from time to time
and its financial reports. Except as required by law, we assume no
obligation to update these forward-looking statements publicly, or to
update the reasons actual results could differ materially from those
anticipated in the forward-looking statements, even if new information
becomes available in the future.
Jennifer Moore, 917-580-1088
KCSA Strategic Communications
Harnest, 646-385-9008
VP of Corporate Strategy and Finance